These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32297120)

  • 1. Synthesis and antitumor evaluation of (aryl)methyl-amine derivatives of dehydroabietic acid-based B ring-fused-thiazole as potential PI3K/AKT/mTOR signaling pathway inhibitors.
    Chen NY; Xie YL; Lu GD; Ye F; Li XY; Huang YW; Huang ML; Chen TY; Li CP
    Mol Divers; 2021 May; 25(2):967-979. PubMed ID: 32297120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, antitumor evaluation and computational study of thiazolidinone derivatives of dehydroabietic acid-based B ring-fused-thiazole.
    Chen NY; Li CP; Huang HF
    Mol Divers; 2024 Apr; 28(2):875-888. PubMed ID: 36862356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway.
    Zhang L; Zheng Y; Zeng L; Zhang F; Che D; Cao Z; Huang C; Xian L; Zhang X; Zhang H; Guo Z
    Life Sci; 2021 Nov; 285():119995. PubMed ID: 34592228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3Kα inhibitors.
    Yang YQ; Chen H; Liu QS; Sun Y; Gu W
    Bioorg Chem; 2020 Jul; 100():103845. PubMed ID: 32344183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X; Zhang B; Luo L; Yang Y; He B; Zhang Q; Wang L; Xu S; Zheng P; Zhu W
    Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.
    Abbas SH; Abd El-Hafeez AA; Shoman ME; Montano MM; Hassan HA
    Bioorg Chem; 2019 Feb; 82():360-377. PubMed ID: 30428415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
    Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
    Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
    Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
    Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tanshinone IIA derivatives induced S-phase arrest through stabilizing c-myc G-quadruplex DNA to regulate ROS-mediated PI3K/Akt/mTOR pathway.
    Wang T; Zou J; Wu Q; Wang R; Yuan CL; Shu J; Zhai BB; Huang XT; Liu NZ; Hua FY; Wang XC; Mei WJ
    Eur J Pharmacol; 2021 Dec; 912():174586. PubMed ID: 34710368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
    Yang Y; Sun X; Luo L; Peng R; Yang R; Cheng Z; Lv Y; Li H; Tang Q; Zhu W; Qiao D; Xu S
    Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300403. PubMed ID: 37840368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
    Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
    Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
    Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.
    Zhang C; Yang N; Yang CH; Ding HS; Luo C; Zhang Y; Wu MJ; Zhang XW; Shen X; Jiang HL; Meng LH; Ding J
    PLoS One; 2009; 4(3):e4881. PubMed ID: 19293927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma.
    Viswanathan A; Kute D; Musa A; Konda Mani S; Sipilä V; Emmert-Streib F; Zubkov FI; Gurbanov AV; Yli-Harja O; Kandhavelu M
    Eur J Med Chem; 2019 Mar; 166():291-303. PubMed ID: 30731398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual blocking of PI3K and mTOR signaling by DHW-221, a novel benzimidazole derivative, exerts antitumor activity in human non-small cell lung cancer.
    Qin X; Liu M; Wu Y; Wang S; Lian S; Jia H; Wu Q; Ding H; Zhao Q
    Clin Transl Med; 2021 Sep; 11(9):e514. PubMed ID: 34586727
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
    Zhao L; Zhang J; Fan Y; Li Y
    Med Sci Monit; 2019 Oct; 25():7864-7871. PubMed ID: 31631173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.